{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:56:32Z","timestamp":1747194992040,"version":"3.40.5"},"reference-count":0,"publisher":"Komitet Redakcyjno - Wydawniczy Polskiego Towarzystwa Psychiatrycznego","issue":"5","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Pol"],"published-print":{"date-parts":[[2021,10,31]]},"abstract":"<jats:p>Leki przeciwpsychotyczne (LPP) z grupy cz\u0119\u015bciowych agonist\u00f3w receptor\u00f3w dopaminowych D2\/D3 (arypiprazol, brekspiprazol, kariprazyna) s\u0105 coraz cz\u0119\u015bciej stosowan\u0105 grup\u0105 lek\u00f3w w leczeniu zaburze\u0144 psychicznych ze wzgl\u0119du na korzystniejszy w por\u00f3wnaniu z innymi LPP profil tolerancji. Artyku\u0142 przedstawia stanowisko na temat stosowania tej grupy lek\u00f3w w leczeniu populacji szczeg\u00f3lnych: os\u00f3b z wsp\u00f3\u0142istniej\u0105cymi chorobami somatycznymi, os\u00f3b w wieku powy\u017cej 65 r.\u017c., w tym os\u00f3b chorych na zespo\u0142y ot\u0119pienne, dzieci i m\u0142odzie\u017cy oraz kobiet w okresie ci\u0105\u017cy oraz karmienia piersi\u0105. Stanowisko zosta\u0142o przygotowane przez zesp\u00f3\u0142 ekspert\u00f3w powo\u0142anych przez Zarz\u0105d G\u0142\u00f3wny Polskiego Towarzystwa Psychiatrycznego, sk\u0142adaj\u0105cy si\u0119 z os\u00f3b z wieloletnim do\u015bwiadczeniem klinicznym w leczeniu os\u00f3b z zaburzeniami psychicznymi. W ocenie uwzgl\u0119dniono analiz\u0119 baz danych pi\u015bmiennictwa, informacje zawarte w charakterystykach produkt\u00f3w leczniczych oraz raportach i rejestrach na temat bezpiecze\u0144stwa ocenianych trzech lek\u00f3w. LPP z grupy cz\u0119\u015bciowych agonist\u00f3w receptor\u00f3w dopaminowych D2\/D3 mog\u0105 by\u0107 stosowne w grupach chorych, w kt\u00f3rych leczeniu konieczne jest zachowanie najwy\u017cszego bezpiecze\u0144stwa terapii.  Wynika to z niskiego ryzyka powodowania przez te leki typowych dla LPP dzia\u0142a\u0144 niepo\u017c\u0105danych: przyrostu masy cia\u0142a i zaburze\u0144 metabolicznych, akatyzji i objaw\u00f3w pozapiramidowych, wzrostu poziomu prolaktyny, wyd\u0142u\u017cenia odst\u0119pu QT w EKG, sedacji oraz objaw\u00f3w zwi\u0105zanych z dzia\u0142aniem cholinolitycznym. Jako stosunkowo kr\u00f3tko dost\u0119pna do leczenia grupa lek\u00f3w, cz\u0119\u015bciowi agoni\u015bci receptor\u00f3w dopaminowych nie posiadaj\u0105 jednak tak licznych danych na temat stosowania w okresie ci\u0105\u017cy jak inne LPP.<\/jats:p>","DOI":"10.12740\/pp\/140287","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T09:54:08Z","timestamp":1640080448000},"page":"967-987","source":"Crossref","is-referenced-by-count":4,"title":["The position statement of the Working Group of the Polish Psychiatric Association on the use of D2\/D3 dopamine receptor partial agonists in special populations"],"prefix":"10.12740","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-601X","authenticated-orcid":false,"given":"Adam","family":"Wichniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rymaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Janas-Kozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wola\u0144czyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Bie\u0144kowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Heitzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Samochowiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5036","published-online":{"date-parts":[[2021,10,31]]},"container-title":["Psychiatria Polska"],"original-title":["Stanowisko grupy roboczej Polskiego Towarzystwa Psychiatrycznego na temat stosowania cz\u0119\u015bciowych agonist\u00f3w receptor\u00f3w dopaminowych D2\/D3 w populacjach szczeg\u00f3lnych"],"link":[{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-140287-81754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-140287-81754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T06:49:09Z","timestamp":1666075749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.psychiatriapolska.pl\/The-position-statement-of-the-Working-Group-of-the-Polish-Psychiatric-Association,140287,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"alternative-id":["140287"],"URL":"https:\/\/doi.org\/10.12740\/pp\/140287","relation":{},"ISSN":["0033-2674","2391-5854"],"issn-type":[{"type":"print","value":"0033-2674"},{"type":"electronic","value":"2391-5854"}],"subject":[],"published":{"date-parts":[[2021,10,31]]}}}